Eosinophilic Gastrointestinal Disorders Registry
This study is a registry designed to learn more about Eosinophilic Gastrointestinal Disorders (EGIDs), which include conditions like Eosinophilic Esophagitis (EoE) and Eosinophilic Colitis. Researchers want to understand the symptoms you experience, your quality of life, how the disease changes with different treatments, and if there's a link between EGIDs and connective tissue disorders. The goal is to gather a lot of information and samples to better understand EGIDs and help develop more precise treatments in the future. You may be able to join if you are between 1 and 25 years old and have an established diagnosis of an EGID or are suspected of having one and are undergoing evaluation.
- Study design
- This is an observational study aiming to enroll 500 participants. It is not testing a specific intervention but rather collecting information over time.
- What's involved
- The study will collect clinical, patient-reported, endoscopic, and physical exam measures through study completion, which averages 6 months to 1 year.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed through study completion, which averages 6 months to 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Eosinophilic Gastrointestinal Disorders Registry
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Joshua B Wechsler, MD · PRINCIPAL_INVESTIGATOR · Ann & Robert H Lurie Children's Hospital of Chicago
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Clinical/Patient-Reported Measuresthrough study completion, an average of 6 months to 1 year
Families complete questionnaires regarding reported symptoms and quality of life as well as family history, patient history and dietary checklists. Change in responses will be assessed at collection timepoints
- Endoscopic measuresthrough study completion, an average of 6 months to 1 year
Endoscopy visual findings will be evaluated using EREFS measurements, which measure the visual findings of Exudates, Rings, Edema, Furrows, and Strictures
- Physical exam findingsthrough study completion, an average of 6 months to 1 year
hypermobility as assessed by Beighton Score, assessed from 5 questions on a 0-2 scale with a higher score reporting a positive association with hypermobility
- Histologic featuresthrough study completion, an average of 6 months to 1 year
Histology markers of eosinophilic esophagitis, specifically eos/hpf, will be assessed at standard of care endoscopies to show change throughout study participation
- Molecular measuresthrough study completion, an average of 6 months to 1 year
In particular, we will assess mast cells and t-cells, and their mediators that are increased in EGIDs